- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01279707
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)
Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)
The treatment of adult B-cell acute lymphoblastic leukaemia (ALL) has progressed considerably in the past 3 decades, particularly due to intensification of chemotherapies, improved supportive care and the incorporation of stem cell transplantation. However, the maximum tolerability of standard chemotherapeutics has been reached in ALL. Using conventional chemotherapy, 80-85% of adults with ALL will achieve a complete remission (CR). Unfortunately treatment at relapse is generally unsuccessful and rarely results, in long-term survival (7% survival at 5 years). Therefore, the investigators are exploring novel treatment strategies through the use of monoclonal antibodies (MoAbs) directed at surface antigens on leukaemic blasts. Using MoAbs directed against surface proteins on B cells has had excellent results in other B-cell diseases such as low and high grade non-Hodgkin lymphomas, without additional toxicity. There has also been limited evidence from small studies and case reports of the efficacy of MoAbs in ALL.
This is a Phase I/II study to determine the safety and tolerability of the combination of veltuzumab and epratuzumab with intensive chemotherapy in patients with relapsed B-cell ALL. A maximum of 51 patients will be treated with a combination of UKALL XII induction chemotherapy and the monoclonal antibodies veltuzumab and epratuzumab. Veltuzumab and epratuzumab are humanised monoclonal antibodies that target CD20 and CD22 surface proteins, respectively. Both of these proteins are expressed on ALL tumour B cells.
One group of patients will receive modified UKALL XII chemotherapy + veltuzumab; a second, modified UKALL XII chemotherapy + epratuzumab and if limited toxicity is found in these first 2 groups, a third group will receive, modified UKALL XII chemotherapy + both veltuzumab and epratuzumab. Patients will be assessed for safety, tolerability and disease response. Safety and tolerability will be measured by the number of Dose Limiting Toxicities (DLTs) in each group. Disease response will be measured by the microscopic appearance of patient bone marrow samples at day 29, and by molecular tests for tumour cells in bone marrow.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom, B15 2TH
- University Hospitals Birmingham NHS Foundation
-
Bristol, United Kingdom, BS2 8BJ
- University of Bristol Foundation Trust
-
Cardiff, United Kingdom, CF14 4XN
- University Hospital of Wales
-
Glasgow, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Centre
-
Leeds, United Kingdom, LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
London, United Kingdom, NW3 2QG
- Royal Free Hampstead NHS Trust
-
London, United Kingdom, EC1A 7BE
- Barts and the London NHS Trust
-
Newcastle, United Kingdom, NE2 4HH
- Newcastle University
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham City Hospital
-
Plymouth, United Kingdom, PL6 8DH
- Plymouth Hospitals Nhs Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 16 years or over
- Confirmed diagnosis of recurrent or refractory B-precursor ALL [according to the WHO classification].
- Greater than 5% blasts in the bone marrow
- WHO/ECOG performance status of 0-2 and well enough to receive intensive combination chemotherapy.
- Negative pregnancy test in women of childbearing potential. Women will not be considered of child bearing potential if they have undergone surgical removal of the uterus or are post menopausal and have been amenorrhoeic for at least 24 months.
Patients must have adequate organ function:
- Renal function - serum creatinine <2.5 x ULN or eGFR>50ml/min (measured EDTA or estimated creatinine clearance e.g Cockcroft & Gault)
- Liver function (bilirubin/ALT <2.5 x ULN)
- Patients must be able to comply with the study schedule.
Exclusion Criteria:
- Patients should not have received chemotherapy for current episode of relapsed ALL (except corticosteroids for a maximum of 10 days, before joining the study).
- Patients with co-morbidities: e.g. uncontrolled hypertension and or poorly controlled diabetes which in the PI's opinion makes them unsuitable for the study.
- Patients with severe psychiatric disorders which in the PI's opinion makes them unsuitable for trial participation.
- Females of childbearing potential and all males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study and for up to 3 months after the last dose of study medication. Note: Subjects are not considered of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
- Females of childbearing potential must have a negative pregnancy test within 7 days prior to starting the study.
- Females must not be breastfeeding.
- Patients may not receive any other investigational agent during the study.
- Patients should not have received any antibody therapy within 3 months of joining this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A: Veltuzumab and chemotherapy
Veltuzumab and modified UKALL XII chemotherapy
|
Veltuzumab with modified UKALL XII induction chemotherapy.
Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
|
Experimental: B: epratuzumab and chemotherapy
epratuzumab and modified UKALL XII chemotherapy
|
Epratuzumab with modified UKALL XII induction chemotherapy.
Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
|
Experimental: C: veltuzumab and epratuzumab and chemotherapy
Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
|
Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy.
Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29.
Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The total number of dose limiting toxicity events (DLTs) to measure safety and tolerability
Time Frame: Day 29
|
The primary objective is to assess the safety and tolerability of the combination of veltuzumab and/or epratuzumab with intensive chemotherapy for recurrent or refractory adult B-precursor ALL.
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphological and molecular remission in bone marrow
Time Frame: Day 29
|
Achievement of morphological complete remission on Day 29 bone marrow Efficacy of treatment to achieve MRD negativity, and investigate a possible association between the intensity of CD20 and CD22 antigen expression and treatment activity. |
Day 29
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew Smith, Doctor, Barts and the London NHS Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia
- Recurrence
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antibodies
- Epratuzumab
- Immunoglobulins
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Veltuzumab
Other Study ID Numbers
- 6125 (Other Identifier: Stanford IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...Netherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
Princess Maxima Center for Pediatric OncologyInnovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids CancerNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryNetherlands
-
National University of MalaysiaGaia ScienceRecruitingRelapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic LeukaemiaMalaysia
-
Fred Hutchinson Cancer CenterJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyTerminatedRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditionsUnited States
-
Sumithira VasuRecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditionsUnited States
-
M.D. Anderson Cancer CenterZiopharm OncologyTerminatedRecurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterFaron Pharmaceuticals LtdNot yet recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell LymphomaUnited States
Clinical Trials on humanised monoclonal antibody, veltuzumab
-
Beth ChristianGilead SciencesCompleted
-
Gilead SciencesCompletedNon-Hodgkin's LymphomaUnited States
-
Ludwig Institute for Cancer ResearchNational Cancer Institute (NCI)CompletedColorectal NeoplasmsAustralia
-
Humanigen, Inc.CompletedChronic Myelomonocytic Leukemia (CMML)United States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
University of ArizonaNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant ConditionUnited States
-
Beijing VDJBio Co., LTD.Completed
-
Shenyang Sunshine Pharmaceutical Co., LTD.Completed
-
National Cancer Institute (NCI)CompletedNeoplasm Metastasis | Breast NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast CarcinomaUnited States